

Curriculum vitae

Antoni Torrens, Ph.D.

1. Experience

Head of Chemical Collaborations & Strategic Alliances - Esteve

2. Organizations

Spanish Society of Medicinal Chemistry (SEQT)

PRESIDENT

September 2011 – Present

European Federation of Medicinal Chemistry (EFMC)

COUNCIL MEMBER

October 2011 – Present

3. Scientific papers (total: 23)

Preetz A, Kohrt C, Drexler H-J, Torrens A, Buschmann H, Lopez MG, Heller D. Asymmetric Ring Opening of Benzo-7-oxabicyclo[2.2.1]heptadienes with Cationic Rhodium Complexes. *Advanced Synthesis & Catalysis* 2010; 352(11-12):2073-2080.

Torrens A, Castrillo JA, Claparols A, Redondo J. ChemInform Abstract: Enantioselective Synthesis of (R)- and (S)-Cizolirtine; Application of Oxazaborolidine-Catalyzed Asymmetric Borane Reduction to Azolyl Phenyl Ketones. *ChemInform* 2010; 30(39).

Brenchat A, Romero L, Garcia M, Pujol M, Burgueno J, Torrens A, Hamon M, Baeyens JM, Buschmann H, Zamanillo D, Vela JM. 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. *Pain* 2009; 141:239-247.

Oliva AI, Christmann U, Font D, Cuevas F, Ballester P, Buschmann H, Torrens A, Yenes S, Pericàs MA. Intramolecular azide-alkyne cycloaddition for the fast assembly of structurally diverse, tricyclic 1,2,3-triazoles. *Organic Letters* 2008; 10(8):1617-1619.

Schwarz N, Pews-Davtyan A, Michalik D, Tillack A, Krüger K, Torrens A, Diaz JL, Beller M. Palladium-Catalyzed Amination and Sulfonylation of 5-Bromo-3-[2-(diethylamino)ethoxy]indoles to Potential 5HT 6 Receptor Ligands. *Annalen der Chemie und Pharmacie* 2008; 2008(32):5425-5435.

Izquierdo S, Aguilera J, Buschmann HH, García M, Torrens A, Ortuño RM. Stereoselective and efficient synthesis of (S)-pregabalin from d-mannitol. *Tetrahedron Asymmetry* 2008; 19(6):651-653.

Torrens A, Mas J, Port A, Castrillo JA, Sanfeliu O, Guitart X, Dordal A, Romero G, Fisas MA, Sánchez E, Hernández E, Pérez P, Pérez R, Buschmann H. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity. *J Med Chem.* 2005; 48(6):2080-2092.

Holenz J, Mercè R, Díaz JL, Guitart X, Codony X, Dordal A, Romero G, Torrens A, Mas J, Andaluz B, Hernández S, Monroy X, Sánchez E, Hernández E, Pérez R, Cubí R, Sanfeliu O, Buschmann H. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. *J Med Chem.* 2005; 48(6):1781-1795.

4. Latest Patents (total: 50)

- **5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics**

Application number: 20130303540

Abstract: The invention relates to pyrazole derivatives of formula I having pharmacological activity and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of pain.

Type: Application

Issued: November 14, 2013

Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.

Inventors: Antoni Torrens Jover, María Rosa Cuberes-Altisen

- **5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors**

Patent number: 8492425

Abstract: The invention relates to compounds having the formula (I): wherein the dashed line (represented by - - -) represents an optional double bond; R1 is hydrogen and R2 is hydroxyethyl; or R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl ring optionally substituted with one or two hydroxy groups; each R3 is independently hydroxy or C1-6alkoxy; n is selected from 0, 1, and 2; or a N-oxide, salt, prodrug, solvate or stereoisomer thereof; with the proviso that the compound where the

dashed line represents a double bond, R1 and R2 together with the nitrogen atom to which they are attached form a morpholinyl ring, and n is 0, is excluded. Also provided are methods for the preparation of compounds of formula (I); their uses as medicaments, particularly for the treatment or prophylaxis of a sigma receptor mediated diseases or conditions.

Type: Grant

Issued: July 23, 2013

Assignee: Laboratories Del Dr. Esteve, S.A.

Inventors: Antoni Torrens Jover, Maria Rosa Cuberes-Altisent, Maria Jose Pretel Sanchez, Maria Magdalena Bordas Gelabert

- **Sigma receptor inhibitors**

Application number: 20130158029

Abstract: The invention refers to compounds of general formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.

Type: Application

Issued: June 20, 2013

Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.

Inventors: Monica Garcia López, Antoni Torrens Jover, José Luis Diaz Fernández, Ana Maria Caamaño Moure

- **Tricyclic triazolic compounds**

Patent number: 8362011

Abstract: The present invention relates to new tricyclic triazolic compounds having a high affinity for sigma-1 receptor as well as to the process for the preparation thereof, to composition comprising them and to their use as medicaments according to compounds of formula (I), Wherein R1 and R2 are as defined in the description.

Type: Grant

Issued: January 29, 2013

Assignee: Laboratories del Dr. Esteve, S.A.

Inventors: Miguel Angel Pericas-Brondo, Antoni Torrens-Jover, Félix Cuevas-Cordobes, Susana Yenes-Minguez

- **Heterocycl-substituted-alkylaminophenyl derivatives, their preparation and use as medicaments**

Application number: 20120322842

Abstract: The present invention relates to heterocycl-substituted alkylamino phenyl derivatives (I) to processes for the preparation thereof, to medicaments comprising them as well as to their use for the preparation of a medicament for the treatment of 5HT7 receptor mediated diseases or conditions. In the compounds (I) x-y-z together form —N—N?CR1— or ?C—NR2—N?.

Type: Application

Issued: December 20, 2012

Assignee: LABORATORIOS DEL DR. ESTEVE, S.A.

Inventors: Monica Garcia-Lopez, Antoni Torrens-Jover, Monica Alonso-Xalma